Physician profile
Robin Dacosta
NPI 1730306507
$606.51
in general payments reported to CMS, 2019-2025
11 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.40 · 2022: $43.66 · 2023: $104 · 2024: $178 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $204.54 | 2024-2025 | |
| Exact Sciences Corporation | $113.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $62.26 | 2022-2024 | Jardiance, Zepbound |
| Amgen INC. | $48.73 | 2024-2025 | Otezla, Repatha, Repatha |
| Idorsia Pharmaceuticals US INC | $35.00 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.95 | 2022 | |
| Glaxosmithkline, LLC. | $31.83 | 2019 | |
| Daiichi Sankyo INC. | $24.70 | 2023 | Injectafer |
| Abbvie INC. | $22.84 | 2025 | |
| Pfizer INC. | $16.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Dacosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.